# PRF-110 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/prf-110

> PRF-110, sponsored by PRF Technologies Ltd. (PRFX): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | PRF-110 |
| Codes | PRF-110 |
| Sponsor | PRF Technologies Ltd. (PRFX) https://sec-api.dev/companies/prfx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar 2023: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-04-07, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003458): "In March 2023, we initiated our first Phase 3 clinical trial of PRF-110 in the United States, for pain treatment of patients undergoing bunionectomy, successfully completing the first part of the Phase 3 clinical study soon thereafter in a PK study of 15 patients undergoing bunionectomy." https://www.sec.gov/Archives/edgar/data/1801834/000117891325003458/exhibit_99-2.htm
- SEC Form 10-K (accession 0001178913-26-001782): "March 2023, we commenced our Phase 3 clinical trial of PRF-110." https://www.sec.gov/Archives/edgar/data/1801834/000117891326001782/zk2634877.htm
- SEC Form 10-K (accession 0001178913-26-001782): "In March 2023, we initiated our first Phase 3 clinical trial of PRF-110 in the United" https://www.sec.gov/Archives/edgar/data/1801834/000117891326001782/zk2634877.htm
- SEC Form 10-K (accession 0001178913-26-001782): "We were able to overcome these issues by further improving the manufacturing process, and in March 2023, we initiated our first Phase 3 clinical trial of PRF-110 in the United States." https://www.sec.gov/Archives/edgar/data/1801834/000117891326001782/zk2634877.htm
- SEC Form 10-K (accession 0001178913-25-001221): "We were able to overcome these issues by further improving the manufacturing process, and in March 2023, we commenced our Phase 3 clinical trial of PRF-110." https://www.sec.gov/Archives/edgar/data/1801834/000117891325001221/zk2532940.htm
- SEC Form 10-K (accession 0001178913-25-001221): "In March 2023, we initiated our first Phase 3 clinical trial of PRF-110 in the United States, for pain treatment of patients undergoing bunionectomy, successfully completing the first part of the Phase 3 clinical study soon thereafter in a PK study of 15 patients undergoing bunionectomy." https://www.sec.gov/Archives/edgar/data/1801834/000117891325001221/zk2532940.htm
- SEC Form 10-K (accession 0001178913-25-001221): "In March 2023, we initiated our first Phase 3 clinical trial of PRF-110 in the United" https://www.sec.gov/Archives/edgar/data/1801834/000117891325001221/zk2532940.htm
- SEC Form 10-K (accession 0001178913-25-001221): "We were able to overcome these issues by further improving the manufacturing process, and in March 2023, we initiated our first Phase 3 clinical trial of PRF-110 in the United States." https://www.sec.gov/Archives/edgar/data/1801834/000117891325001221/zk2532940.htm

### Nov 2024: topline data readout

- Status: completed, met. Date confidence: month.
- First seen 2025-04-07, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003458): "In November 2024, we announced that the initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery." https://www.sec.gov/Archives/edgar/data/1801834/000117891325003458/exhibit_99-2.htm
- SEC Form 10-K (accession 0001178913-26-001782): "In November 2024, we announced that the initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery." https://www.sec.gov/Archives/edgar/data/1801834/000117891326001782/zk2634877.htm
- SEC Form 10-K (accession 0001178913-25-001221): "In November 2024, we announced that the initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery." https://www.sec.gov/Archives/edgar/data/1801834/000117891325001221/zk2532940.htm
- SEC Form 10-K (accession 0001178913-25-001221): "In total, 428 patients have been enrolled at eight clinical sites across the U.S. In November 2024, we announced initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery." https://www.sec.gov/Archives/edgar/data/1801834/000117891325001221/zk2532940.htm

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-04-28, last confirmed 2026-04-28.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002264): "Following IND clearance and completion of trial-startup activities, PRF plans to initiate a multi-center Phase II clinical trial in the United States, with patient enrollment expected to begin in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1801834/000117891326002264/exhibit_99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/prf-110.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PRF-110 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/prf-110

```bibtex
@misc{secapidev_pdufa_prf_110_20261116,
  title        = {PRF-110 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/prf-110}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_prf_110_20261116","title":"PRF-110 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/prf-110","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
